Home » Topics » BioWorld Science, Endocrine/metabolic

BioWorld Science, Endocrine/metabolic
RSS

FDA issues complete response letter regarding Byuderon NDA

Oct. 21, 2010

New diacylglycerol O-acyltransferase 1 inhibitors disclosed

Oct. 21, 2010

Treatment begins in phase I/II alpha-1-antitrypsin trial in type 1 diabetes

Oct. 21, 2010

Zealand Pharma's ZP-2307 shows bone anabolic activity in vivo

Oct. 21, 2010

Merck & Co. claims new diacylglycerol O-acyltransferase 1 inhibitors

Oct. 20, 2010

FDA grants fast track status for HPN-100 in urea cycle disorders

Oct. 20, 2010

DiaMedica reports final data from DM-99 study in type 1 diabetes

Oct. 20, 2010

Pfizer presents new GPR119 receptor agonists

Oct. 18, 2010

Merck & Co. claims new diacylglycerol O-acyltransferase 1 inhibitors

Oct. 15, 2010

FDA warns of increased risk of thigh bone fracture with bisphosphonates use

Oct. 15, 2010

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 17, 2026.
AAIC 2026: Age of amyloid is being joined by time of tau
BioWorld
The Alzheimer’s Association International Conference (AAIC) is the world’s biggest dementia conference. And at the AAIC 2026 meeting, there is big buzz around...
Celia trial: data strong, analysts skeptical
BioWorld
Tuesday brought what was arguably the most anticipated presentation of the 2026 Alzheimer’s Association International Conference when Catherine Mummery, head of...
News in brief
BioWorld Asia
BioWorld Asia briefs for July 14, 2026
Voyager’s gene therapy reduces tau levels in AD models
BioWorld Science
At the Alzheimer’s Association International Conference, researchers from Voyager Therapeutics Inc. presented preclinical efficacy data for VY-1706, a blood-brain...